Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.4
Journals
JCDD
Special Issues
Biomarkers for Heart Failure Diagnosis, Prognosis and Guidance of Therapy
share announcement

Biomarkers for Heart Failure Diagnosis, Prognosis and Guidance of Therapy

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Cardiovascular Clinical Research".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 5984

Special Issue Editors

Dr. Peder Langeland Myhre

E-Mail Website
Guest Editor
1. Department of Cardiology, Division of Medicine, Akershus University Hospital, 1474 Lørenskog, Norway
2. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0315 Oslo, Norway
Interests: cardiovascular biomarkers; heart failure; cardiovascular prevention; risk prediction
Dr. Thomas A. Zelniker

E-Mail Website
Guest Editor
Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria
Interests: interplay of obesity; metabolic health and cardiovascular disease; heart failure; prevention of cardiovascular disease; biomarkers and genetics of cardiovascular disease

Special Issue Information

Dear Colleagues,

The Journal of Cardiovascular Development and Disease is planning to create a Special Issue that focuses on biomarkers in heart failure (HF). In this Special Issue, we will highlight some recent developments advancing the assessment of the diagnosis, prognosis, and guidance of therapy in HF. The use of natriuretic peptides is well established and strongly recommended by current guidelines in multiple settings of HF. Several other promising biomarkers are being investigated to improve the ability to correctly diagnose HF, predict outcomes and monitor treatment. A dedicated analysis of patients with HF with reduced ejection fraction (HFrEF), patients with HF with preserved ejection fraction and advanced HF are warranted as these conditions are distinct with respect to clinical characteristics, but also biomarker profiles. In this Special Issue “Biomarkers for Heart Failure Diagnosis, Prognosis and Guidance of Therapy”, we welcome you to contribute a research paper or review article on any aspect of this topic including novel basic science or clinical approaches that better define the mechanisms or improve clinical care of patients with HF. This is an excellent opportunity for clinical and basic sciences trainees in your group to contribute to the field.

Dr. Peder Langeland Myhre
Dr. Thomas A. Zelniker
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • heart failure
  • HFpEF
  • HFrEF
  • diagnosis
  • prognosis
  • treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

11 pages, 559 KiB  
Review
Biomarkers for Heart Failure Prediction and Prevention
by Prasanti Alekhya Kotta, Vijay Nambi and Biykem Bozkurt
J. Cardiovasc. Dev. Dis. 2023, 10(12), 488; https://doi.org/10.3390/jcdd10120488 - 6 Dec 2023
Cited by 2 | Viewed by 2190
Abstract
Heart failure (HF) is a global pandemic affecting over 64 million people worldwide. Its prevalence is on an upward trajectory, with associated increasing healthcare expenditure. Organizations including the American College of Cardiology (ACC) and the American Heart Association (AHA) have identified HF prevention [...] Read more.
Heart failure (HF) is a global pandemic affecting over 64 million people worldwide. Its prevalence is on an upward trajectory, with associated increasing healthcare expenditure. Organizations including the American College of Cardiology (ACC) and the American Heart Association (AHA) have identified HF prevention as an important focus. Recently, the ACC/AHA/Heart Failure Society of America (HFSA) Guidelines on heart failure were updated with a new Class IIa, Level of Evidence B recommendation for biomarker-based screening in patients at risk of developing heart failure. In this review, we evaluate the studies that have assessed the various roles and contributions of biomarkers in the prediction and prevention of heart failure. We examined studies that have utilized biomarkers to detect cardiac dysfunction or abnormality for HF risk prediction and screening before patients develop clinical signs and symptoms of HF. We also included studies with biomarkers on prognostication and risk prediction over and above existing HF risk prediction models and studies that address the utility of changes in biomarkers over time for HF risk. We discuss studies of biomarkers to guide management and assess the efficacy of prevention strategies and multi-biomarker and multimodality approaches to improve risk prediction. Full article
(This article belongs to the Special Issue Biomarkers for Heart Failure Diagnosis, Prognosis and Guidance of Therapy)
►▼ Show Figures

Figure 1

15 pages, 1163 KiB  
Review
Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide
by Mauro Riccardi, Peder L. Myhre, Thomas A. Zelniker, Marco Metra, James L. Januzzi and Riccardo M. Inciardi
J. Cardiovasc. Dev. Dis. 2023, 10(11), 468; https://doi.org/10.3390/jcdd10110468 - 17 Nov 2023
Cited by 7 | Viewed by 3205
Abstract
Soluble (s)ST2 has been proposed as a useful biomarker for heart failure (HF) patient management. Myocardial damage or mechanical stress stimulate sST2 release. ST2 competes with a membrane bound receptor (ST2 ligand, or ST2L) for interleukin-33 (IL-33) binding, inhibiting the effects induced by [...] Read more.
Soluble (s)ST2 has been proposed as a useful biomarker for heart failure (HF) patient management. Myocardial damage or mechanical stress stimulate sST2 release. ST2 competes with a membrane bound receptor (ST2 ligand, or ST2L) for interleukin-33 (IL-33) binding, inhibiting the effects induced by the ST2L/IL-33 interaction so that excessive sST2 may contribute to myocardial fibrosis and ventricular remodeling. Compared to natriuretic peptides (NPs), sST2 concentration is not substantially affected by age, sex, body mass index, kidney function, atrial fibrillation, anemia, or HF etiology, and has low intra-individual variation. Its prognostic role as an independent marker is well reported in the literature. However, there is a gap on its use in combination with NPs, currently the only biomarkers recommended by European and American guidelines for HF management. Reflecting the activation of two distinct biological systems, a benefit from the use of sST2 and NP in combination is advocated. The aim of this review is to report the current scientific knowledge on sST2 in the acute and chronic HF settings with a particular attention to its additive role to natriuretic peptides (NPs). Full article
(This article belongs to the Special Issue Biomarkers for Heart Failure Diagnosis, Prognosis and Guidance of Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop